Abstracts tagged "Real World Evidence"

Abstract Number: 0296 • ACR Convergence 2021
The Impact of Delayed Primary Sjögren’s Syndrome Diagnosis on Patient Outcomes: A Real-World Survey in the US
Briana Ndife¹, Sophie Barlow², Megan Hughes² and Nicola Booth², ¹Novartis, East Hanover, NJ, ²Adelphi Real World, Bollington, United Kingdom
Background/Purpose: Diagnosis of primary Sjögren’s syndrome (pSS) is challenging due to the disease’s phenotypic heterogeneity. pSS patients frequently experience a prolonged period between symptomatic onset…
Abstract Number: 0297 • ACR Convergence 2021
Describing the Disease Burden of Primary Sjögren’s Syndrome Patients: Results from a Real-World Survey in the US
Briana Ndife¹, Ben Hoskin², Megan Hughes² and Nicola Booth², ¹Novartis, East Hanover, NJ, ²Adelphi Real World, Bollington, United Kingdom
Background/Purpose: Primary Sjogren’s syndrome is a highly heterogeneous condition, with limited understanding of the burden of disease. The objective of this study was to describe…
Abstract Number: 1365 • 2019 ACR/ARP Annual Meeting
Construct Validation of PROMIS Short Form and Profile-29 T-Scores with SF-36 in Rheumatoid Arthritis Patients Treated for 1 Year: Results from a Real World Evidence-Based Study in the United States
Clifton Bingham¹, Shelly Kafka ², Shawn Black ³, Stephen Xu ⁴ and Jeffrey Curtis ⁵, ¹Johns Hopkins University, Baltimore, MD, ²Janssen Scientific Affairs, LLC, Horsham, PA, ³Janssen Scientific Affairs, LLC, Horsham, RI, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Use of PROs to assess health-related quality of life in clinical practice, research studies, and clinical trials in Rheumatoid Arthritis (RA) remains an ongoing…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].